Lantheus (NASDAQ:LNTH) Upgraded at William Blair

William Blair upgraded shares of Lantheus (NASDAQ:LNTH) from a market perform rating to an outperform rating in a research note released on Thursday, Marketbeat reports.

LNTH has been the subject of a number of other reports. Mizuho boosted their price objective on Lantheus from $60.00 to $72.00 and gave the stock an “outperform” rating in a report on Wednesday, December 17th. Citizens Jmp lifted their target price on Lantheus from $73.00 to $78.00 and gave the company a “market outperform” rating in a research report on Tuesday, February 24th. Citigroup reiterated an “outperform” rating on shares of Lantheus in a report on Tuesday. Weiss Ratings raised Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 6th. Finally, Truist Financial lifted their price objective on shares of Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a report on Thursday, December 18th. Seven analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $82.17.

Lantheus Stock Performance

LNTH opened at $74.91 on Thursday. Lantheus has a 1-year low of $47.25 and a 1-year high of $111.29. The company has a market cap of $4.97 billion, a price-to-earnings ratio of 22.23 and a beta of -0.08. The company’s fifty day moving average price is $68.15 and its two-hundred day moving average price is $60.19. The company has a current ratio of 2.67, a quick ratio of 2.49 and a debt-to-equity ratio of 0.51.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 EPS for the quarter, topping the consensus estimate of $1.17 by $0.50. Lantheus had a net margin of 15.15% and a return on equity of 30.37%. The company had revenue of $406.79 million during the quarter, compared to the consensus estimate of $367.03 million. During the same period in the previous year, the firm posted $1.59 earnings per share. The firm’s revenue for the quarter was up 4.0% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, analysts expect that Lantheus will post 6.01 EPS for the current fiscal year.

Institutional Investors Weigh In On Lantheus

Several large investors have recently made changes to their positions in LNTH. Villanova Investment Management Co LLC purchased a new position in shares of Lantheus in the 4th quarter worth about $1,511,000. Alberta Investment Management Corp bought a new stake in Lantheus in the fourth quarter worth about $1,617,000. Vident Advisory LLC raised its position in Lantheus by 0.5% in the fourth quarter. Vident Advisory LLC now owns 44,763 shares of the medical equipment provider’s stock worth $2,979,000 after acquiring an additional 230 shares during the period. Mackenzie Financial Corp boosted its stake in Lantheus by 31.1% in the fourth quarter. Mackenzie Financial Corp now owns 657,674 shares of the medical equipment provider’s stock valued at $44,082,000 after acquiring an additional 156,081 shares during the last quarter. Finally, XTX Topco Ltd grew its position in shares of Lantheus by 64.8% during the 4th quarter. XTX Topco Ltd now owns 18,440 shares of the medical equipment provider’s stock valued at $1,227,000 after acquiring an additional 7,252 shares during the period. 99.06% of the stock is owned by hedge funds and other institutional investors.

More Lantheus News

Here are the key news stories impacting Lantheus this week:

• Positive Sentiment: Q4 results: Lantheus reported $1.67 EPS vs. $1.17 expected and revenue of $406.8M vs. $367.0M expected (revenue +4% y/y), showing operational strength and margin improvement. MarketBeat Earnings Report
• Positive Sentiment: Mizuho raised its price target to $85 and set an “outperform” rating, signaling increased analyst conviction and implied upside from current levels. Benzinga
• Positive Sentiment: William Blair upgraded Lantheus from “market perform” to “outperform,” adding another positive analyst endorsement. Street Insider
• Positive Sentiment: Citizens Jmp raised its price target to $78, a modest endorsement that supports the view of upside among some sell‑side analysts. American Banking News
• Neutral Sentiment: JonesTrading reaffirmed a “hold” rating on LNTH, reflecting mixed views on near‑term catalysts. TickerReport
• Neutral Sentiment: Investor materials and transcripts are available (earnings call transcript and presentation), useful for digging into product trends, margin drivers and pipeline commentary. Yahoo Finance Transcript Seeking Alpha Deck
• Negative Sentiment: FY2026 guidance was mixed: EPS guidance of $5.00–$5.25 is roughly in line with consensus (5.16), but revenue guidance of $1.4B–$1.5B leaves room for a slight top‑line miss vs. expectations — a conservative revenue range that could weigh on near‑term sentiment. GlobeNewswire Press Release

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.